- Report
- January 2026
- 183 Pages
Global
From €3450EUR$3,939USD£2,994GBP
- Report
- February 2026
- 369 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- February 2026
- 283 Pages
Global
From €5124EUR$5,850USD£4,447GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- April 2025
- 175 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- July 2025
- 350 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- June 2025
- 150 Pages
Global
From €2364EUR$2,699USD£2,052GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2443EUR$2,789USD£2,120GBP
- Report
- March 2025
- 146 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- September 2025
- 150 Pages
Global
From €3372EUR$3,850USD£2,927GBP
€4248EUR$4,850USD£3,687GBP
- Report
- June 2025
- 250 Pages
United States
From €2443EUR$2,789USD£2,120GBP
- Report
- February 2023
- 130 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- August 2024
- 178 Pages
Global
From €3941EUR$4,500USD£3,421GBP
- Report
- June 2025
- 250 Pages
India
From €2443EUR$2,789USD£2,120GBP
- Report
- June 2025
- 250 Pages
Japan
From €2443EUR$2,789USD£2,120GBP
Bedaquiline is a drug used to treat tuberculosis (TB). It is a member of the diarylquinoline class of drugs, and is the first new TB drug to be approved by the US Food and Drug Administration (FDA) in over 40 years. It is used to treat multi-drug resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Bedaquiline is administered as an oral tablet and is usually taken in combination with other TB drugs.
Bedaquiline is part of the respiratory drug market, which includes drugs used to treat a variety of respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. The market is highly competitive, with many companies developing and marketing drugs to treat respiratory diseases.
Some companies in the Bedaquiline market include Johnson & Johnson, Otsuka Pharmaceuticals, and Mylan. Show Less Read more
